Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s):  CPHRF

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, and Vaniqa. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. It also has the Natroba operations and global product rights to Natroba and its authorized generic Spinosad, a topical treatment for both head lice and scabies.


TSX:CPH - Post by User

Comment by Stocker46on May 13, 2021 6:56pm
207 Views
Post# 33200439

RE:Q1

RE:Q1Negatives:
Net Earnings (after adusting for Trulance) was significantly less than 4th Q 2020 (which tends to be their strongest quarter)

Positives:
Trulance (we hope) is now over & done with.
Generated $4.3M in Cash ending the Q with $13.3M US Dollars
No Debt .. this time last year they had about $6M in Debt.

Will be intesting to see how the market reacts tomorrow.

And yes, some strange late trading. I actually sold a small portion of my shares (to buy another stock). just before the close. When I put in the ask at $1.40, there was only a 1 lot bid at $1.36.
Got my $1.40 & then it moved to $1.60 in the last minute or 2 of trading. (??) 


<< Previous
Bullboard Posts
Next >>